Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts

Award Number: R21AI195147
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/02/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts - PROJECT SUMMARY Cryptococcal meningoencephalitis (CME) is responsible for more than 15% of the total deaths of AIDS patients. The disease claims hundreds of thousands of lives each year, with global mortality rates of ~70% de- spite antifungal therapies. Unfortunately, there is no vaccine clinically available or in clinical trials for cryptococ- cosis. We previously showed that the morphotype of this fungus has a profound effect on its interaction with various hosts. In mammalian models of cryptococcosis, the yeast form is pathogenic while the filamentous form is not. We established that the transcription factor Znf2, which drives filamentous growth, is a powerful anti-virulence regulator. Cryptococcal cells overexpressing ZNF2 (ZNF2oe) are avirulent and elicit strong and long-lasting protective immunity, which serves as an effective vaccine against subsequent lethal challenges. Importantly, we showed that once mice are vaccinated with ZNF2oe cells, their CD4+ T cells are dispen- sable for protection at the time of fungal challenge. Furthermore, vaccination with ZNF2oe cells pro- vides significant protection against cryptococcosis even in hosts with pre-existing CD4+ T cell defi- ciency (mimics AIDS patients). These findings are important because the majority of cryptococcosis patients are AIDS patients with low CD4+ T cell counts, and our preclinical studies suggest that cryptococcal vaccines could be effective in these individuals. The specific goals of this exploratory R21 application are to identify cell types (Aim 1) and cytokine profiles (Aim 2) important for ZNF2oe vaccine-induced immunity and host protection in CD4+ T cell-defi- cient hosts. The findings from the proposed work will identify correlates of protection (COPs) that will help guide the design of safer and effective subunit protein vaccines or nucleic acid-based vaccines in the future. Our long-term goal is to develop vaccines that could protect the most vulnerable populations from deadly cryp- tococcal meningoencephalitis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $400,932 )
2026	2026	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	310 E CAMPUS RD RM 409	ATHENS	GA	30602	CLARKE	USA	Allergy and Infectious Diseases Research	000	1	2/2/2026	NEW	$400,932
														Subtotal = $400,932

Grand Total All Awards = $400,932

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts

Award Number: R21AI195147

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/02/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer